The Rising Global Burden of Diabetes and its Complications: Estimates and Projections to the Year 2010

Amos, Angelyn; McCarty, Daniel J.; Zimmet, Paul

doi:10.1002/(sici)1096-9136(199712)14:5+<s7::aid-dia522>3.3.co;2-i

Cited by 1,306 publications

(981 citation statements)

References 22 publications

Supporting

Mentioning

938

Contrasting

Unclassified

Order By: Relevance

“…Diabetes mellitus is a common disease and its prevalence is expected to increase in the future, especially in developing countries [1,2]. As recently as 1995, an estimated 135 million peop1e worldwide were affected by diabetes and by the year 2025, this figure is projected to increase to approximately 300 million [3].…”

Section: :S5-s 12]mentioning

confidence: 99%

Revealing the cost of Type II diabetes in Europe

2002

View full text Add to dashboard Cite

Aims/hypothesis. 'The Cost of Diabetes in EuropeType II study' is the first coordinated attempt to measure total healthcare costs of Type II (non-insulindependent) diabetes mellitus in Europe. The study evaluated more than 7000 patients with Type II diabetes in eight countries -Belgium, France, Germany, Italy, the Netherlands, Spain, Sweden and the United Kingdom. Methods. A bottom-up, prevalence-based design was used, which optimised the collection of data at the national level while maintaining maximum international comparability. Effort was made to ensure consistency in terms of data specification, data collection tools and methods, sampling design, and the analysis and reporting of results. Results are reported for individual countries and in aggregate for the total study population. Results. The total direct medical costs of Type II diabetes in the eight European countries was estimated at EUR 29 billion a year (1999 values). The estimated average yearly cost per patient was EUR 2834 a year. Of these costs, hospitalisations accounted for the greatest proportion (55%, range 30-65%) totalling EUR 15.9 billion for the eight countries. During the 6-month evaluation period, 13% of the Type II diabetic patients were hospitalised, with an average of 23 days in hospital projected annually. In contrast, drug costs for managing Type II diabetes were relatively low, with antidiabetic drugs and insulin accounting for only 7% of the total healthcare costs for Type 11 diabetes. Conclusionlinterpretation. Type 11 diabetes mellitus is a common disease and the prevalence is expected to increase considerably in the future, especially in developing countries. Current comprehensive economic data on the costs of diabetes are required for policy decisions to optimise resource allocation and to evaluate different approaches for disease management. [Diabetologia (2002) 45:S5-S 12]

show abstract

Section: :S5-s 12]mentioning

confidence: 99%

Revealing the cost of Type II diabetes in Europe

2002

View full text Add to dashboard Cite

show abstract

“…The two main classes, ''insulin-dependent diabetes'' (IDDM or type-1) and noninsulin-dependent diabetes'' (NIDDM or type-2) are easily distinguished by the severity of insulin deficiency, which is more profound in IDDM (Pickup & Williams 1997). However, NIDDM is becoming an ever greater public health problem, currently affecting an estimated 150 million people worldwide (Amos et al 1997). NIDDM is characterAuthor for correspondence: Sebastian Barg, Department of Physiological Sciences, Molecular and Cellular Physiology, Lund University, Sö lvegatan 19, BMC F11, S-221 84 Lund, Sweden (fax π46 222 7763, e-mail sebastian.barg/mphy.lu.se).…”

Section: The Importance Of Insulinmentioning

confidence: 99%

Mechanisms of Exocytosis in Insulin‐Secreting B‐Cells and Glucagon‐Secreting A‐Cells

Barg

2003

Pharmacology & Toxicology

View full text Add to dashboard Cite

In pancreatic B-and A-cells, metabolic stimuli regulate biochemical and electrical processes that culminate in Ca 2π -influx and release of insulin or glucagon, respectively. Like in other (neuro)endocrine cells, Ca 2π -influx triggers the rapid exocytosis of hormone-containing secretory granules. Only a small fraction of granules (Ͻ1% in insulin-secreting B-cells) can be released immediately, while the remainder requires translocation to the plasma membrane and further ''priming'' for release by several ATP-and Ca 2π -dependent reactions. Such functional organization may account for systemic features such as the biphasic time course of glucose-stimulated insulin secretion. Since this release pattern is altered in type-2 diabetes mellitus, it is conceivable that disturbances in the exocytotic machinery underlie the disease. Here I will review recent data from our laboratory relevant for the understanding of these processes in insulin-secreting B-cells and glucagon-secreting A-cells and for the identification of novel targets for antidiabetic drug action. Two aspects are discussed in detail: 1) The importance of a tight interaction between L-type Ca 2π -channels and the exocytotic machinery for efficient secretion; and 2) the role of intragranular acidification for the priming of secretory granules and its regulation by a granular 65-kDa sulfonylurea-binding protein.

show abstract

“…The current consensus is that immediate debridement surgery is necessary as soon as the infection is clinically diagnosed [5]. Series of debridement procedures, which may be required to achieve complete cleaning of the wound, can take the medical doctor to decide for amputation [4].…”

Section: Introductionmentioning

confidence: 99%

Is surgical debridement necessary in the diabetic foot treated with photodynamic therapy?

Tardivo

Serrano

Zimmermann

et al. 2017

Diabetic Foot & Ankle

View full text Add to dashboard Cite

Background: Diabetic patients are susceptible to developing foot ulcers with serious complications such as osteomyelitis and amputations. Treatment approaches are still empirical and the benefit of usual procedures such as surgical debridement has not been properly evaluated. Photodynamic Therapy (PDT) is a non-invasive and highly efficient method for the treatment of the diabetic foot, being able to eradicate the infection and to stimulate healing, decreasing considerably the amputation risk. In the day-to-day practice of our service, we have been faced with the question whether debridement is necessary before PDT. In here, we designed a study to answer that question. Methods: Patients were divided in two groups: In one of the groups (n = 17), debridement was performed before PDT and in the other (n = 40) only PDT treatment was performed. PDT sessions were performed once a week in all patients until healing was achieved, as indicated by visual inspection as well as by radiographic and laboratory exams. At the start of the study, the two groups had no statistical differences concerning their clinical features: average age, gender, insulin use, diabetes mellitus onset time and previous amputations. Results: PDT was effective in the treatment of 100% of the patients showing no relapses after one year of follow up. The group submitted to PDT without previous debridement had a statistically significant (p = 0.036, Mann-Whitney) shorter cure time (29 days, ~27%). Conclusion: Our data indicates that debridement is not necessary in the treatment of diabetic foot in patients that have enough peripheral arterial perfusion. In addition, we reproduced previous studies confirming that PDT is an efficient, safe, simple and affordable treatment method for the diabetic foot.

show abstract

The Rising Global Burden of Diabetes and its Complications: Estimates and Projections to the Year 2010

Cited by 1,306 publications

References 22 publications

Revealing the cost of Type II diabetes in Europe

Revealing the cost of Type II diabetes in Europe

Mechanisms of Exocytosis in Insulin‐Secreting B‐Cells and Glucagon‐Secreting A‐Cells

Is surgical debridement necessary in the diabetic foot treated with photodynamic therapy?

Contact Info

Product

Resources

About